Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation trial of BI 3819026 + ezabenlimab in advanced solid tumors
jRCT2031260026Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of BI 3819026 and ezabenlimab in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), breast cancer and 3 more, sponsored by Boehringer Ingelheim. Primary endpoint: Dose-limiting toxicities in primary DLT evaluation period. Started Apr 2026; status: recruiting.
02
Drugs
BI 3819026ezabenlimab
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)breast cancermelanomahepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2031260026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260026.